Table 3.

Action of lycopene in improving the impairment of other diseases.

Lycopene doses	Method	Impairment	Improvement	Lit. cited
0.2 mg/kg b.w. daily	In vivo–rats	Cataract	Significant delayed in the onset and progression of galactose cataract and reduced the incidence of selenite cataract.	145
2.5, 5 and 10 mg/kg b.w. daily	In vivo–rats	Cognitive function	Significant improved in memory.	143
60 mg/kg b.w. daily	In vivo–hyperlipemia rabbits	Lipid peroxidation injury	Significant reduced in the levels of serum TG and MDA, increase serum SOD activity, increase serum NO.	146
0.1, 0.5, 1, 2 g/kg b.w. daily	In vivo– mouse ear oedema model	Swelling	Decreased swelling of the croton oil-induced ear.	147
0, 5 and 10 μg/mLcarried by liposomes	In vitro–Calu-3 cells	Inflammation of cells infected by rhinovirus or exposed to lipopolysaccharide	Reduced the release of interleukin-6 and interferon-gamma induced protein-10.	148
8 or 16 mg/kg/day by i.p. injection	In vivo–murine model of asthma	Ovalbumin-induced inflammation	Significant inhibition of the infiltration of inflammatory immunocytes into the bronchoalveolar lavage.	149
2 mgtwice daily	In vivo–primigravida women	Pre-eclampsia and intrauterinegrowth retardation	Significant reduced in pre-eclamsia incidence and intrauterine growth retardation in the lycopene group compare to placebo group.	150
9 mg/kg b.w. twice a day for 2 weeks	In vivo–rats	Chronic bacterial prostatitis	Significant decreased in bacterial growth and improvement of prostatic inflammation.	151
0.025–2 mg per 20 mg b.w.	In vivo–white heterozygote mouse	X-ray radiation lesions	Moderate curative effect on the radiation lesions and increased survival rate	152